Colon Cancer: An Educational Overview

What it is

Colon cancer is a malignancy that arises from the inner lining of the large intestine, most often beginning as a benign growth, an adenomatous or serrated polyp, that gradually accumulates genetic and epigenetic changes over years before some lesions become invasive. The large majority of these tumors are adenocarcinomas, meaning they originate in the glandular epithelium of the bowel wall. Because the precursor lesions develop slowly and are frequently visible and removable during endoscopy, colon cancer is one of the few common cancers that screening can prevent outright, not detect early. Together with rectal cancer, it is usually grouped under the umbrella term colorectal cancer (CRC), and most population statistics are reported for the combined category.

How common it is

Colorectal cancer is the fourth most commonly diagnosed cancer in the United States and the second leading cause of cancer death [1]. The age-adjusted incidence is approximately 37.6 new cases per 100,000 people per year (2019, 2023) [1], translating to more than 150,000 new colorectal diagnoses and over 52,000 deaths annually, with colon cancer making up the larger share of that total [2]. The estimated lifetime risk of being diagnosed with colorectal cancer is roughly 3.9%, or about 1 in 24 to 26 people [1].

The overall trend is encouraging but uneven. Total incidence has been declining by roughly 0.5% per year, largely attributable to screening and polyp removal [1]. However, incidence is rising in adults younger than 50, so-called early-onset colorectal cancer, a shift important enough to have changed screening policy [1][2]. Mortality follows a parallel pattern: deaths are falling overall (with around 55,230 colorectal deaths projected for 2026) but increasing among younger adults [2].

Who's at risk factors fall into two broad groups. Non-modifiable factors include increasing age, although the early-onset trend complicates the traditional assumption that this is a disease of older adults [1], and inherited cancer syndromes such as Lynch syndrome (caused by defective mismatch-repair genes) and familial adenomatous polyposis (driven by APC mutations), along with a strong family history of the disease. Long-standing inflammatory bowel disease (ulcerative colitis or Crohn colitis) and a personal history of advanced adenomas or serrated lesions also raise risk and cannot be changed.

Modifiable factors center on diet and lifestyle: diets high in processed and red meat and low in fiber, obesity, physical inactivity, alcohol use, and smoking are all associated with higher risk. The evidence linking these exposures to colorectal cancer is consistent, though the magnitude of any single factor's contribution at the individual level is harder to quantify, and these associations describe populations rather than guaranteeing any one person's outcome.

How it's found

Several screening modalities are available, each with different performance characteristics and burdens: colonoscopy, fecal immunochemical testing (FIT) and other high-sensitivity stool tests, stool DNA testing, CT colonography, and flexible sigmoidoscopy. Colonoscopy is distinctive because it both detects and removes precursor polyps in the same procedure.

Neutrally summarized, the US Preventive Services Task Force recommends screening for average-risk adults beginning at age 45 and continuing through 75, with screening between ages 76 and 85 individualized to the person's health and history; people at higher risk because of hereditary syndromes or family history may begin earlier [3]. The starting age was lowered to 45 specifically in response to the rise in early-onset disease [3]. This overview describes guideline content for educational purposes and is not a recommendation directed at any individual reader.

When colon cancer presents symptomatically rather than through screening, common features include a change in bowel habits, rectal bleeding or blood in the stool, abdominal discomfort, or unexplained iron-deficiency anemia [1]. Many cancers, however, are found on screening before any symptoms appear, which is part of the rationale for structured screening programs.

Outlook

Survival depends heavily on how far the cancer has spread at diagnosis. Using relative five-year survival figures, colorectal cancer detected while still localized (confined to the bowel wall) is associated with survival around 91%; regional disease (spread to nearby lymph nodes) with about 73%; and distant disease (spread to organs such as the liver or lungs) with roughly 13, 18% [1]. Across all stages combined, relative five-year survival is approximately 65% [1].

These are population statistics, not individual predictions. They are derived from large groups of people diagnosed in past years and averaged across ages, biology, treatments, and overall health. They cannot tell any single person what will happen to them. An individual's outlook is shaped by tumor biology, molecular features, treatment response, other medical conditions, and factors not captured in stage alone, and treatments continue to evolve, meaning historical survival data may understate what is achievable today. These numbers are best understood as orientation, not destiny.

How it's diagnosed and classified

Diagnosis is confirmed by biopsy and microscopic (histopathologic) examination of tissue, which establishes the tumor type. Most colon cancers are adenocarcinoma, not otherwise specified, but distinct subtypes, mucinous adenocarcinoma, signet-ring cell carcinoma, and the separate family of neuroendocrine neoplasms (ranging from well-differentiated NETs grade 1, 3 to neuroendocrine carcinoma and mixed neuroendocrine, non-neuroendocrine neoplasms), carry different biology and behavior. This pathologic classification, combined with stage, forms the foundation on which subsequent molecular characterization is built.

How treatment is guided

Beyond histology and stage, molecular biomarkers increasingly inform which therapy classes a patient may be eligible to consider. Key themes include mismatch-repair/microsatellite-instability status (dMMR/MSI-H) [4], RAS (KRAS/NRAS) [5] and BRAF V600E mutations [6], HER2 (ERBB2) amplification [7], NTRK fusions [8], and circulating tumor DNA (ctDNA) used to assess minimal residual disease [9]. These markers help define eligibility for broad treatment categories rather than dictating any individual's regimen, and how best to use several of them, particularly ctDNA for residual-disease monitoring, remains an active, fast-moving area of investigation. Decisions about treatment for any specific person are made with their care team.

---

References

1. National Cancer Institute. SEER Cancer Stat Facts (SEER*Explorer; 2019, 2023 incidence, 2020, 2024 mortality, 2016, 2022 survival). seer.cancer.gov/statfacts. 2026 release.

2. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026. doi:10.3322/caac.70043.

3. US Preventive Services Task Force. Colorectal Cancer: Screening (2021 Recommendation). uspreventiveservicestaskforce.org. 2021.

4. Le DT, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017. PMID 28596308. doi:10.1126/science.aan6733., Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015. PMID 26028255. doi:10.1056/NEJMoa1500596., Hampel H, et al. Screening for the Lynch syndrome (HNPCC). N Engl J Med. 2005. PMID 15872200., Hampel H, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008. PMID 18809606. doi:10.1200/JCO.2008.17.5950., Beamer LC, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome. J Clin Oncol. 2012. PMID 22355048. doi:10.1200/JCO.2011.38.4719.

5. Lièvre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008. PMID 18202412. doi:10.1200/JCO.2007.12.5906., Amado RG, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008. PMID 18316791. doi:10.1200/JCO.2007.14.7116., Douillard JY, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME). N Engl J Med. 2013. PMID 24024839. doi:10.1056/NEJMoa1305275.

6. Kopetz S, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E, mutated colorectal cancer (BEACON CRC). N Engl J Med. 2019. PMID 31566309. doi:10.1056/NEJMoa1908075., Dvorak K, et al. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody in colorectal cancer. Pathology. 2014. PMID 25014730. doi:10.1097/PAT.0000000000000119.

7. Valtorta E, et al. Assessment of a HER2 scoring system for colorectal cancer. Mod Pathol. 2015. PMID 26449765. doi:10.1038/modpathol.2015.98., Sartore-Bianchi A, et al. Dual-targeted therapy with trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer (HERACLES). Lancet Oncol. 2016. PMID 27108243., Cenaj O, et al. ERBB2 amplification/HER2 status by NGS in colorectal cancer. Am J Clin Pathol. 2019. PMID 31115453. doi:10.1093/ajcp/aqz031., Sartore-Bianchi A, et al. HER2 and anti-EGFR resistance in colorectal cancer. Oncologist. 2019. PMID 30952821. doi:10.1634/theoncologist.2018-0785., Strickler JH, et al. Tucatinib plus trastuzumab for HER2-positive metastatic colorectal cancer (MOUNTAINEER). Lancet Oncol. 2023. PMID 37142372. doi:10.1016/S1470-2045(23)00150-X.

8. Hechtman JF, et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for detection of NTRK fusions. Am J Surg Pathol. 2017. PMID 28719467. doi:10.1097/PAS.0000000000000911., Solomon JP, et al. NTRK fusion detection across multiple assays. Mod Pathol. 2020. PMID 31375766. doi:10.1038/s41379-019-0324-7., Cocco E, et al. Colorectal carcinomas containing hypermethylated MLH1 promoter and kinase fusions. Cancer Res. 2019. PMID 30643016., Drilon A, et al. Safety and antitumor activity of entrectinib in NTRK fusion-positive tumors. Cancer Discov. 2017. PMID 28183697. doi:10.1158/2159-8290.CD-16-1237., Drilon A, et al. Efficacy of larotrectinib in TRK fusion-positive cancers. N Engl J Med. 2018. PMID 29466156. doi:10.1056/NEJMoa1714448.

9. Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer (DYNAMIC). N Engl J Med. 2022. PMID 35657320. doi:10.1056/NEJMoa2200075., Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016. PMID 27384348. doi:10.1126/scitranslmed.aaf6219., Reinert T, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I, III colorectal cancer. JAMA Oncol. 2019. PMID 31070691. doi:10.1001/jamaoncol.2019.0528., Kotani D, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in colorectal cancer (GALAXY/CIRCULATE-Japan). Nat Med. 2023. PMID 36646802. doi:10.1038/s41591-022-02115-4., Henriksen TV, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection. Clin Cancer Res. 2022. PMID 34625408. doi:10.1158/1078-0432.CCR-21-2404.